You Position: Home > Paper
Multidisciplinary treatment and neoadjuvant therapy of pancreatic cancer
( views:0, downloads:0 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Pancreatology
- Issue:
- 5
- DOI:
- 10.3760/cma.j.cn115667-20200831-00142
- Key Word:
- 胰腺癌;多学科诊治;新辅助治疗;Pancreatic cancer;Multidisciplinary treatment;Neoadjuvant therapy
Abstract： As a new direction of pancreatic cancer treatment, neoadjuvant therapy for pancreatic cancer has been confirmed to be able to improve the prognosis of the patients. Under multidisciplinary treatment (MDT) mode, neoadjuvant therapy combines multidisciplinary advantages to solve patients′ problems of diagnosis and treatment, provides accurate, comprehensive and individual treatments, and maximizes the clinical benefit for patients. In this article, we summarize the present problems of neoadjuvant therapy for pancreatic cancer in patient selection, treatment regimen selection, treatment response evaluation and surgical selection, and explore the direction of clinical research and neoadjuvant therapy for pancreatic cancer under MDT mode.
- [1]中华医学会肿瘤学分会胰腺癌学组(筹).胰腺癌多学科综合治疗协作组专家共识[J].2013,(5).
- [2]钱家鸣,吴东.消化科医师在胰腺癌多学科诊疗中的作用[J].2017,(1).
- [3]中国研究型医院学会消化道肿瘤专业委员会,中国医师协会外科医师分会多学科综合治疗专业委员会.胰腺癌多学科综合治疗协作组诊疗模式专家共识[J].2017,(1).
- [4]Versteijne E.,Vogel J. A.,Besselink M. G.,etc.Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer[J].2018,105(8).
- [5]Mark J,Truty,Michael L,Kendrick,David M,Nagorney,etc.Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.[J].2019.
- [6]Hirohisa KITAGAWA.Resectability classification in pancreatic cancer in the 7th Edition of General Rules for the Study of Pancreatic Cancer by the Japan Pancreas Society[J].2016,(6).
- [7].Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review.[J].2019,12.
- [8]Beleù, Alessandro,Calabrese, Angela,Rizzo, Giulio,etc.Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study[J].2019,11(2).
- [9]Matthew HG Katz Peter WT Pisters,Jeffrey E Lee,Charlotte C Sun,etc.Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease[J].2008,206(5).
- [10]Siegel Rebecca L.,Miller Kimberly D.,Jemal Ahmedin.Cancer statistics, 2020[J].2020,70(1).
- [11]Klaiber, Ulla,Leonhardt, Carl-Stephan,Strobel, Oliver,etc.Neoadjuvant and adjuvant chemotherapy in pancreatic cancer[J].2018,403(8).
- [12]Michelakos, Theodoros,Pergolini, Ilaria,Fernandez-del Castillo, Carlos,etc.Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX[J].2019,269(4).
- [13].Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer[J].2020,27(3).
- [14]Kirkeg?rd J.,Aahlin E. K.,Al‐Saiddi M.,etc.Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation[J].2019,106(6).
- [15]Kim, Bo Ram,Kim, Jung Hoon,Ahn, Su Joa,etc.CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis[J].2019,29(1).
- [16]Wang,H.,Katz,M.H.G.,Abbruzzese,J.,etc.Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators[J].2012,118(23).
- [17]Donahue TR,Isacoff WH,Hines OJ,etc.Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.[J].2011,146(7).
- [18]Barreto Savio G.,Loveday Benjamin,Windsor John A.,etc.Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer[J].2019,89(5).
- [19]Macedo, Francis, I,Ryon, Emily,Maithel, Shishir K.,etc.Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer[J].2019,270(3).
- [20]Syed A. Ahmad,Mai Duong,Davendra P. S. Sohal,etc.Surgical Outcome Results From SWOG S1505[J].2020,272(3).